SCHEMBL699754

SCHEMBL699754

CN1CC[C@H](Oc2ccc(/N=C3/NC(=O)/C(=C/c4cnc(NC(=O)C5CC5)s4)S3)c(C(F)(F)F)c2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.38
BRAF P15056 4/20 0.38
SOS1 Q07889 2/20 0.36
TXK P42681 3/20 0.35
ITK Q08881 3/20 0.35
JAK3 P52333 2/20 0.35
PIM1 P11309 2/20 0.35
NTRK1 P04629 1/20 0.35
DAPK1 P53355 1/20 0.35
KCNH2 Q12809 1/20 0.35
PIM3 Q86V86 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
MKNK1 Q9BUB5 1/20 0.34
DYRK3 O43781 1/20 0.34
GCK P35557 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
WNT1 P04628 1/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10176526 0.97 KDR (0.39) KDRBRAFSOS1TXKITK
SCHEMBL10176507 0.90 MAPT (0.40) TXKJAK3MKNK1GCKGPR119
SCHEMBL650221 0.90 ABL1 (0.36) TXKITKJAK3DYRK3ABL1
SCHEMBL10176525 0.90 ABL1 (0.36) TXKITKJAK3DYRK3ABL1
SCHEMBL651145 0.87 RNASEL (0.40) MKNK1DYRK3GPR119WNT1GSK3B
SCHEMBL10176480 0.87 MAPT (0.41) MKNK1GPR119WNT1GSK3BDYRK1A
SCHEMBL652215 0.83 HPGD (0.36) TXKITKJAK3DYRK3ABL1
SCHEMBL653891 0.80 MAPT (0.41) GPR119ABL1
SCHEMBL653892 0.80 MAPT (0.41) GPR119ABL1
SCHEMBL697898 0.79 MAPT (0.43) ITKMKNK1WNT1GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 KDR 4523/4885BRAF 2249/4885SOS1 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.